Intraocular pressure lowering efficacy and safety of travoprost 0.004 % as a replacement therapy in patients with open angle glaucoma or ocular hypertension

作     者：GE Jian SUN Xing-huai WANG Ning-li ZHAO Jia-liang WU Ling-ling CHEN Xiao-ming WANG Zhi-xin Benny Li 

作者机构：Zhongshan Ophtllalmic Center State Key Laboratory ofOphthalmology Sun Yat-sen University Guangzhou Guangdong510060 China Department of Ophtthalmology Eye Ear Nose and Throat HospitalSchool of Medicine Fudan University Shanghai 200031 China Beijing Tongren Eye Center Beijing Tongren Hospital CapitalMedical University Beijing Ophthalmology & Visual SciencesKey Laboratory Beijing 100730 China Department of Ophthalmology Peking Union Medical CollegeHospital Chinese Academy of Medical Sciences Beijing 100730China Peking University Eye Center Peking University Third HospitalBeijing 100191 China Depal~ment of Ophthalmology West China Hospital SichuanUniversity Chengdu Sichuan 610041 China Alcon Research Ltd. 6201 South Freeway Fort Worth Texas76134 USA 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2010年第123卷第11期

页      面：1417-1421页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 0905[农学-畜牧学] 09[农学] 090501[农学-动物遗传育种与繁殖] 10[医学] 

基　　金：Alcon Research Ltd.  Fort Worth  TX 

主　　题：travoprost prostaglandin analogue intraocular pressure glaucoma 

摘      要：Background Travoprost has been widely used for the treatment of patients with open-angle glaucoma （OAG） or ocular hypertension （OH）. The aim of this study was to evaluate the intraocular pressure （lOP） lowering efficacy of travoprost 0.004% monotherapy in patients previously treated with other topical hypotensive medications, and in previously untreated patients. Methods This open-label, 12-week study in 1651 adult patients with ocular hypertension or open-angle glaucoma who were untreated or required a change in therapy （due to either inadequate efficacy or safety issues） as judged by the investigator was conducted at 6 sites in China. Previously treated patients were instructed to discontinue their prior medications at the first visit. All the patients were dosed with travoprost 0.004% once-daily at 8 p.m. in both eyes for 12 weeks. Efficacy and safety evaluations were conducted at week 4 and 12. lOP measurements were performed at the same time of day at the follow-up visits. Results For patients transitioned to travoprost, mean lOP reductions from baseline in untreated and treated patients with different prior medications at week 12 were： latanoprost, （4.3±4.6） mmHg; β-blocker, （6.3±4.0） mmHg; α-agonist, （7.5±4.3） mmHg; topical carbonic anhydrase inhibitors, （8.0±4.9） mmHg. All mean lOP changes from baseline were statistically significant （P 〈0.001）. No treatment-related serious adverse events were reported in this study. Conclusions In patients treated with other hypotensive medications or untreated, the lOP reduction with travoprost was significant. The results of this study demonstrated the potential benefit of using travoprost as a replacement therapy in order to ensure adequate lOP control. Travoprost administered once daily was safe and well tolerated in patients with glaucoma or ocular hypertension.